Nasdaq
$8.24▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.6MShares out 0.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 9.8Pre-market26.08.15 06:00filed10-QEarnings#●●●#●●●
Bone Biologics Corp
Bone Biologics reported cash and cash equivalents of $4,031,780 as of June 30, 2026. As of August 14, 2026, the company has 2,756,057 shares of common stock outstanding.…more
$8.24+0.00%vs prev closeView filingShare
- 9.8Pre-market26.07.18 06:14filedS-3Offering
Bone Biologics Corp
Bone Biologics has filed an S-3 registration statement for up to 6,464,792 shares of common stock issuable upon the exercise of warrants issued in a private placement that closed on July 9, 2026. This filing facilitates the potential exercise of these warrants by selling stockholders, and the company will not receive any proceeds from these sales.…more
$8.24+0.00%vs prev closeView filingShare - 9.8Pre-market26.07.17 06:25filed8-KKey event
Bone Biologics Corp
Bone Biologics Corporation has postponed its 2026 annual meeting of stockholders, originally scheduled for August 11, 2026, to September 28, 2026. This decision was made to allow for the filing of an additional proposal in the proxy statement and to provide stockholders with sufficient time to review the materials.…more
$8.24+0.00%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.8Pre-market26.09.08 21:30#●●●#●●●#●●●
Bone Biologics Expands Clinical Trial Sites for NB1
Bone Biologics has doubled its clinical trial sites in Australia to six, aiming to complete patient enrollment by the end of 2026. While this expansion is intended to accelerate the pilot study, the company remains in the early stages of clinical development.…more
$8.24+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.3Pre-market26.09.03 21:30
●●●●●●●● ●●●●● ●●●●●●
Bone Biologics announced its participation in the upcoming H.C. Wainwright 28th Annual Global Investment Conference to engage with investors. The event will feature one-on-one meetings and a virtual presentation, though no specific financial or operational milestones were disclosed.…more
$8.24+0.00%vs prev close - 7.23Pre-market26.07.23 21:00
●●●●●●●● ●●●●● ●●●●●●
본 바이올로직스는 최근 300만 달러 규모의 자금 조달을 완료하여 2027년 2분기까지 NB1 임상 개발, 제조 준비, 지적 재산권 확보를 위한 자금을 확보했습니다. 또한 rhNELL-1 단백질의 유효 기간을 29개월로 연장하여 제조 및 공급망 유연성을 강화했습니다.…more
$8.24+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report